News
3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates
Last year, the Federal Reserve began hiking interest rates in an effort to slow down the economy. Today, interest rates are at their highest levels since the early 2000s. For many businesses, an
Is Sarepta Therapeutics Stock a Bad-News Buy?
Investing in biotech stocks is risky. And one of the more volatile ones of late is Sarepta Therapeutics (NASDAQ: SRPT). Shares of the company crashed last week after it released results from phase 3
2 Soaring Stocks to Buy and Hold
Biotech giant Regeneron (NASDAQ: REGN) and streaming specialist Roku (NASDAQ: ROKU) have been solid performers for most of the year, but both stocks recently jumped following their third-quarter
This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues
Vertex Pharmaceuticals (NASDAQ: VRTX) generates billions of dollars in annual revenues from its treatments for the rare disease cystic fibrosis. And Vertex should continue to dominate in cystic
EQS-News: RHÖN-KLINIKUM AG increases consolidated profit and revenues
Invitae (NVTA) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Invitae (NYSE: NVTA)Q3 2023 Earnings CallNov 08, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Biogen (BIIB) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q3 2023 Earnings CallNov 08, 2023, 8:00 a.m. ET
Operator
Source Fool.com
1 Gene Therapy Stock to Buy and Hold for the Long Haul
Biotech companies working on gene therapies have made significant strides lately, but many of them remain relatively risky stocks. Still, gene therapies have the potential to help transform medicine
Why CRISPR Therapeutics Stock Could Be About to Take Off
CRISPR Therapeutics (NASDAQ: CRSP) is a company that doesn't have an approved product on the market. Its operations are unprofitable, and it is burning through cash. There are many reasons that this
2 Medical Device Companies Experiencing Strong Demand Even as Weight-Loss Drugs Rise in Popularity
There's a growing fear among investors that weight-loss drugs and treatments such as Ozempic could negatively impact many businesses, from food companies to healthcare businesses. But there are a
4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked
Some investors might be at least a little more nervous about Vertex Pharmaceuticals (NASDAQ: VRTX) now than they were only a few days ago. Why? The big biopharmaceutical company provided its
EQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate update
MannKind (MNKD) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
MannKind (NASDAQ: MNKD)Q3 2023 Earnings CallNov 07, 2023, 5:00 p.m. ET
Operator
Source Fool.com
Why Sage Therapeutics Stock Sank Today
It wasn't a wise move for investors to hold or buy Sage Therapeutics (NASDAQ: SAGE) shares on Tuesday. Its price tumbled by nearly 5% as the market digested the healthcare company's third-quarter
Why Coherus Biosciences Stock Dropped Today
Shares of Coherus Biosciences (NASDAQ: CHRS) were down by about 30% as of 3:25 p.m. ET Tuesday after the company announced disappointing third-quarter results and lowered its full-year guidance.
Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
2 Monster Stocks to Buy Without Any Hesitation
While the phrase "monster stocks" might generally have investors thinking of Tesla, Apple, or similar behemoths, the two businesses discussed in this article are sneakily monstrous.
First, consumer
MacroGenics (MGNX) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
MacroGenics (NASDAQ: MGNX)Q3 2023 Earnings CallNov 06, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals (VRTX) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q3 2023 Earnings CallNov 06, 2023, 4:30 p.m. ET
Operator
Source Fool.com
EQS-News: Evotec and Dewpoint Therapeutics enter strategic partnership in oncology
Why Celldex Therapeutics Blasted 13% Higher on Monday
Clinical-stage biotech Celldex Therapeutics (NASDAQ: CLDX) was a standout on the stock market Monday. The company's share price closed a sturdy 13% higher on the day, thanks to freshly published
Axsome Therapeutics (AXSM) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Axsome Therapeutics (NASDAQ: AXSM)Q3 2023 Earnings CallNov 06, 2023, 8:00 a.m. ET
Operator
Source Fool.com
3 Spectacular High-Yield Dividend Stocks to Buy in November
Not all dividend stocks are in the same league. Some offer puny yields. Others, though, provide exceptionally high ones plus solid long-term growth prospects.
Three Motley Fool contributors think
3 Things About Invitae Every Smart Investor Knows
Genetic-testing company, Invitae (NYSE: NVTA), isn't as easy to understand as it might seem. After more than a year of pivoting and scaling down its operations, changing its leadership, and
1 Under-the-Radar Stock That Could Triple By 2030
Weight-loss medicines are rising in popularity. According to some estimates, this market will be worth $44 billion in risk-adjusted sales by 2030, while it was only valued at $2.5 billion last year